SAN DIEGO, March 4, 2015 /PRNewswire/ -- Imprimis
Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company
focused on the development and commercialization of proprietary
compounded drug therapies, today reported that it will release its
fourth quarter and fiscal year 2014 financial results on
Thursday, March 12, 2015. The
company will host a conference call at 4:30
p.m. EDT (1:30 p.m. PDT) on
the same day to discuss its financial results and report on recent
business activities. The conference call and webcast will be
open to all listeners and a question and answer session will follow
the prepared remarks.
To participate in this event, dial 877-407-8035 domestically, or
201-689-8035 internationally, approximately 5 to 10 minutes prior
to the start of the call. Additionally, you can listen to the
event online at http://www.investorcalendar.com/event/173699, as
well as at the company's website at
www.imprimispharma.com. If you are unable to participate
during the live webcast, the event archive will be available at
http://www.investorcalendar.com/event/173699 or at the company's
website at www.imprimispharma.com. You may access the
teleconference replay by dialing 877-660-6853 domestically or
201-612-7415 internationally, referencing conference
13602837. The replay will be available until April 12, 2015.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis
Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company
dedicated to delivering high quality and innovative medicines to
physicians and patients at accessible prices. Imprimis'
business is focused on its proprietary ophthalmology and urology
drug formulations. The company's pioneering ophthalmology
formulation portfolio is disrupting the multi-billion dollar eye
drop market, addressing patient compliance issues and providing
other medical and economic benefits to patients. Imprimis
expects to launch its urology business in 2015, which includes a
patented formulation to address patients suffering from
interstitial cystitis. For more information about Imprimis,
please visit the company's corporate website at
www.ImprimisPharma.com; ophthalmology business website at
www.GoDropless.com; and urology business website at
www.DefeatIC.com.
SAFE HARBOR
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward looking statements." Forward
looking statements are based on management's current expectations
and are subject to risks and uncertainties which may cause results
to differ materially and adversely from the statements contained
herein. Some of the potential risks and uncertainties that could
cause actual results to differ from those predicted include risks
and uncertainties related to Imprimis' ability to make commercially
available its compounded formulations and technologies in a timely
manner or at all; physician interest in prescribing its
formulations; risks related to its compounding pharmacy operations;
its ability to enter into other strategic alliances, including
arrangements with pharmacies, physicians and healthcare
organizations for the development and distribution of its
formulations; its ability to obtain intellectual property
protection for its assets; its ability to accurately estimate its
expenses and cash burn, and raise additional funds when necessary;
risks related to research and development activities; the projected
size of the potential market for its technologies and formulations;
unexpected new data, safety and technical issues; regulatory and
market developments impacting compounding pharmacies, outsourcing
facilities and the pharmaceutical industry; competition; and market
conditions. These and additional risks and uncertainties are more
fully described in Imprimis' filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q. Such documents may be read free
of charge on the SEC's web site at www.sec.gov. Undue reliance
should not be placed on forward-looking statements, which speak
only as of the date they are made. Except as required by law,
Imprimis undertakes no obligation to update any forward looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Contact
Bonnie Ortega
Imprimis Pharmaceuticals
bortega@imprimispharma.com
858.704.4587
Logo - http://photos.prnewswire.com/prnh/20150108/167712LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-to-host-its-fourth-quarter-and-fiscal-year-2014-financial-report-conference-call-and-webcast-on-march-12-2015-at-430-pm-edt-300045144.html
SOURCE Imprimis Pharmaceuticals, Inc.